On April 17, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), reported that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The MATISSE study (NCT05742607) is a single arm Phase 2 clinical trial evaluating perioperative IPH5201, an anti-CD39 blocking antibody, in combination with perioperative durvalumab (anti-PD-L1) in addition to neoadjuvant platinum-based chemotherapy in previously untreated patients with resectable NSCLC. The trial is designed to assess whether dual inhibition of the CD39 and PD-L1 pathways, together with chemotherapy, can enhance anti-tumor immune responses and improve clinical outcomes in early-stage lung cancer.

These results follow a pre-planned interim analysis on 40 patients. The combination of IPH5201 with durvalumab and chemotherapy demonstrated higher pathological complete response (pCR) rates compared with the benchmark set by durvalumab plus chemotherapy alone. Notably, pCR was 35.7% and 50% in patients with tumors expressing PD-L1 ≥1% and PD-L1 ≥50%, respectively. Based on these results, the study continues to recruit patients with tumors expressing PD-L1≥1%.

"Patients with resectable NSCLC remain at significant risk of recurrence, underscoring the need for novel perioperative treatment strategies. Disrupting the adenosine pathway through CD39 inhibition with IPH5201, in combination with PD-1 blockade and chemotherapy, could enhance anti-tumor immune responses—particularly in patients with PD-L1 positive tumors, where we observed up to 50% pCR rate in the MATISSE trial. This signal will be further investigated as we complete enrollment of the study in the PD-L1-positive population," commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.

The presentation will be available in the publication section of Innate Pharma’s website.

Abstract details
Dual CD39 and PD-L1 inhibition: Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable NSCLC
Abstract Code: CT231
Session: CTPL04 – Advances in Immunotherapy
Session Date/Time: Tuesday, April 21, 2026, 10:45 – 11:00 AM PDT
Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy

About IPH5201
IPH5201 is a first-in-class monoclonal antibody targeting CD39, a key immunosuppressive enzyme in the adenosine pathway. CD39 is expressed on tumor-infiltrating immune and stromal cells and contributes to immunosuppression by degrading extracellular adenosine triphosphate (ATP) into adenosine monophosphate (AMP), which is then further degraded into adenosine by CD73. By blocking CD39, IPH5201 promotes the accumulation of immunostimulatory ATP and reduces the production of immunosuppressive adenosine, thereby enhancing anti-tumor immune responses.
IPH5201 is being co-developed in collaboration with AstraZeneca and is currently being evaluated in the Phase 2 MATISSE trial (NCT05742607), a multicenter study investigating perioperative treatment with IPH5201 in combination with durvalumab (anti-PD-L1) and platinum-based chemotherapy in patients with resectable non-small cell lung cancer (NSCLC).
The MATISSE trial is designed to assess anti-tumor activity, including pathological complete response, and safety, with the goal of determining whether dual inhibition of the CD39 and PD-L1 pathways, in combination with chemotherapy, can enhance anti-tumor immunity and improve clinical outcomes in early-stage NSCLC.

(Press release, Innate Pharma, APR 17, 2026, View Source [SID1234664471])

On April 17, 2026 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, reported that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics’ PRAME T-cell receptor (TCR) has been accepted for a late-breaking poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, California, USA. The patient case will be presented on April 21, 2026, at 2:00 pm PDT (Late-Breaking Research: Clinical Research 3; Poster Section 52; Poster Board Number 7; Abstract Number LB326) by the treating physician, Dr. med. Christian M. Seitz, Group Leader at the Hopp Children’s Cancer Center Heidelberg (KiTZ).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract highlights the case of a 17-year-old adolescent with PRAME-positive advanced nephroblastoma, a malignant kidney cancer that predominantly occurs in children. The patient had rapidly progressing disease with metastases to the lung, liver and brain with an abdominal lesion measuring 16 cm in longest diameter. After exhausting all available treatment options and being ineligible for any ongoing clinical trial, the treating physician requested Immatics’ PRAME-directed TCR (encoded by the IMA203CD8 lentiviral vector) for an individual experimental treatment attempt (named-patient use; "Individueller Heilversuch" in Germany) at KiTZ, where a TCR T-cell therapy was manufactured. Following treatment, the patient experienced a deep anti-tumor response, with remission observed three months post-infusion and ongoing at six months of follow-up. PET scan and MRI imaging demonstrated marked tumor regression across all lesion sites. Additionally, liquid biopsy monitoring showed no more tumor-derived DNA, indicating molecular remission. Safety events reported in the abstract by the treating physician included cytokine release syndrome, which was manageable and resolved under multi-modal anti-cytokine therapy and corticosteroids. At six months of follow-up, the patient is in excellent physical condition.

"We are very grateful to Immatics for providing the PRAME-directed TCR that enabled us to reprogram the pediatric patient’s cells. We hope that possible further clinical evaluation may demonstrate the potential of PRAME-targeted cellular immunotherapies in helping other children and adolescents with cancer, as seen in this patient," said Christian M. Seitz, M.D., treating physician and Group Leader of the Translational Immunotherapy group at KiTZ, German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD).

About Immatics’ PRAME-Directed Cell Therapie

Immatics is developing PRAME-directed TCR T-cell therapies engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01 on the surface of tumor cells and to initiate a potent and specific anti-tumor response.

Immatics’ PRAME-directed cell therapies are being evaluated in clinical trials across multiple PRAME-positive solid tumors in adult patients. Its lead PRAME cell therapy candidate, anzu-cel (anzutresgene autoleucel, IMA203) is currently being evaluated in a registration-enabling Phase 3 trial "SUPRAME" in previously treated advanced cutaneous melanoma and a Phase 2 trial in metastatic uveal melanoma. In addition, Immatics is evaluating its second-generation PRAME cell therapy, IMA203CD8, in a Phase 1a dose escalation trial in patients with PRAME-positive solid tumors, with a focus on gynecologic cancers.

About PRAME

PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and two combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy (GEN2), IMA402 PRAME bispecific as monotherapy and in combination with an immune checkpoint inhibitor as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy.
Cedrik Britten, M.D., Ph.D., Chief Medical Officer at Immatics, added, "Seeing such a profound response in a pediatric patient who had no treatment options left is both remarkable and deeply encouraging for everyone dedicated to making a meaningful impact on the lives of patients with cancer. It reinforces our belief in PRAME as a powerful target and highlights the potential of cell therapy for pediatric cancers, where tumors often show high PRAME expression. These results support continued evaluation of PRAME-directed cell therapies in pediatric cancers while exploring new therapeutic options for children facing such devastating diseases."

PRAME is a tumor target present on the cell surface of more than 50 cancers and can be targeted by TCR T-cell therapies. Based on the high PRAME expression across multiple different pediatric tumors in combination with the potential benefit of particularly strong immune responses in young patients, PRAME TCR T-cell therapies may offer a promising new treatment option for these patients. Immatics is planning to evaluate the potential of its PRAME TCR T-cell therapy candidates in pediatric patients with cancer and is assessing multiple options for clinical development including a potential first-in-pediatrics Phase 1/2 basket study in pediatric patients with HLA-A*02:01-positive, PRAME-expressing relapsed or refractory solid tumors at KiTZ in Heidelberg.

(Press release, Immatics, APR 17, 2026, View Source [SID1234664470])

On April 17, 2026 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported that preclinical data from the Company’s KRAS and ErbB2 pipeline programs will be presented during poster sessions at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place in April 17-22 in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we prepare for the potential launch of bezuclastinib later this year, we are excited to share updates from two of our pipeline programs this weekend at the 2026 annual AACR (Free AACR Whitepaper) meeting," said Andrew Robbins, Cogent’s President and Chief Executive Officer. "First, we are presenting data on CGT1263, our novel pan-KRAS(ON) inhibitor, which shows best-in-class cellular potency along with evidence that its kinase selectivity advantage over multi-RAS inhibitors could drive clinical differentiation with regards to skin toxicity, a current liability of advanced clinical programs. Separately, we provide an update on CGT4255, our novel, selective ErbB2 inhibitor that was specifically designed for its best-in-class CNS penetrant properties to address a significant unmet need for HER2+ patients with brain metastases. This presentation also includes preclinical data in combination with a HER2 ADC suggesting potential synergistic activity leading to improved duration of therapy as well as re-sensitization of patients following HER2 ADC resistance. With multiple potential blockbuster programs advancing in our pipeline, we believe these new data underscore the long-term potential of Cogent Biosciences."

Poster Details

Title: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 1
Session Date and Time: April 19, 2026 – 2:00 PM – 5:00 PM PT (5:00 PM – 8:00 PM ET)
Location: Poster Section 17
Poster Board Number: 13
Poster Number: 410

Mutations in KRAS are among the most prevalent mutations found in cancer, occurring most often in colorectal cancer, non-small cell lung cancer and pancreatic cancer. The preclinical poster highlights Cogent’s internally developed pan-KRAS(ON) inhibitor with >500x selectivity for KRAS over HRAS and NRAS. Plasma exposure following oral administration across species resulted in sustained pERK inhibition and robust antitumor activity. Tumor pERK inhibition was also achieved with limited skin suppression, supporting the potential of a larger therapeutic window for CGT1263 when compared to multi-RAS inhibitors currently in clinical development. This aligns with historical data implicating the RAS-MAPK-ERK pathway as essential for skin development given its role in regulation of keratinocyte proliferation, differentiation, and survival; combined suppression of multiple targets within this pathway is thought to be the driver of frequent rash observed in patients treated with multi-RAS inhibitors. Overall, these findings suggest CGT1263 could provide an advantage for patients, enabling higher dosing designed to elicit a more profound molecular response. Investigational New Drug (IND) enabling studies are ongoing with an IND submission expected later this year.

Title: Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase, Phosphatase, and Other Inhibitors
Session Date and Time: April 21, 2026 – 2:00 PM – 5:00 PM PT (5:00 PM – 8:00 PM ET)
Location: Poster Section 18
Poster Board Number: 7
Poster Number: 5869

Cogent’s EGFR-sparing, brain-penetrant ErbB2 inhibitor includes potent coverage of key mutations (YVMA, S310F, V842I, L755S) inadequately addressed by currently approved therapies. Activating mutations in the ErbB2 gene have been identified in multiple cancers and demonstrate a tumorigenic role similar to that of ErbB2 amplification. New data presented describe CGT4255’s >100-fold selectivity over EGFR while robustly engaging HER2 amplification, insertion and mutant lines in addition to reinforcing best-in-class potential CNS performance relative to other agents in development. Additional mechanistic studies presented suggest CGT4255 may have synergistic effects on efficacy and durability when combined with HER2 targeted ADCs. Preclinical evidence demonstrates that concurrent treatment of CGT4255 and T-DXd enhances receptor internalization and cancer cell apoptosis, suggesting the potential for a synergistic combination that could improve patient outcomes. The Phase 1 study of CGT4255 is ongoing.

Posters will be available on the ‘Posters and Publications’ page of Cogent’s website.

(Press release, Cogent Biosciences, APR 17, 2026, View Source [SID1234664468])

On April 17, 2026 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, reported that it will be presenting a poster on its lead asset AT-108 at the AACR (Free AACR Whitepaper) Annual Meeting, held in San Diego, California, US, from 17-22 April 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AT-108 is a transformative gene therapy utilizing Asgard’s in vivo cell reprogramming technology to directly reprogram tumor cells into dendritic cells. This approach forces these tumor cells to present their tumor antigens, ultimately leading to a personalized anti-tumor immune response. Asgard is progressing its first-in-class therapy toward clinical development, with a focus on solid tumors, and is advancing IND-enabling studies and CMC development.

The poster presentation, titled ‘Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent’, will detail preclinical data demonstrating that AT-108 induces systemic, dose-dependent efficacy with broad tumor activity. Key biomarker parameters were highlighted to be explored in future clinical development.

Details of the poster presentation are as follow:

Poster title: Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent

Presenter: Fabio Rosa, Asgard Therapeutics

Authors: Fritiof Åkerström1, Xavier Catena1, Marta Santiago2, Ana Perego1, Ruixian Liu1, Arun Sundaramurthy1, Lihan Xie1, Emilie Renaud1, Andreea-Medeea Matei1, Xiaoli Huang1, Emma Leire1, Ozcan Met2, Inge-Marie Svane2, Shane Olwill1, Cristiana Pires1, Filipe Pereira3, Fabio Rosa1

Poster session: Session LBPO.ET04 – Late-Breaking Research: Experimental and Molecular Therapeutics 4

Session date and time: 22 April, 2026, 9:00 AM – 12:00 PM PDT

Location: Section 53

Poster number: LB455 / 2

1Asgard Therapeutics AB, Lund, Sweden,2National Center of Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark,3Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, Lund, Sweden

The abstract is available to view via the AACR (Free AACR Whitepaper) online planner.

(Press release, Asgard Therapeutics, APR 17, 2026, View Source [SID1234664467])

On April 17, 2026 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, reported new data from two ongoing Phase 1b/2 studies of muzastotug in triple combination regimens at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting 2026, held April 17-22 in San Diego. Results support muzastotug’s mechanistic advantages over traditional anti-CTLA-4 therapies, and its continued development as a potential backbone therapy in combination regimens for difficult-to-treat cancers. FDA has previously designated muzastotug in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as a Fast Track product for adult patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) without current or active liver metastases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At AACR (Free AACR Whitepaper), Adagene shared new data from two triplet regimens supporting muzastotug’s potential as a combination backbone for multiple tumor types, said Peter Luo, Ph.D., CEO and President of R&D at Adagene. In HCC, adding muzastotug to the atezolizumab plus bevacizumab combo resulted in higher efficacy, with a safety profile consistent with historical studies of the doublet alone. In MSS CRC, adding muzastotug to pembrolizumab plus fruquintinib showed dose-dependent response rates, with no DLTs or Grade 4 or 5 treatment related adverse events. As muzastotug continues to generate more data in additional settings, we are increasingly convinced that its intentionally designed wider therapeutic index has potential to improve the efficacy of current immunotherapies without worsening the toxicity for patients with difficult to treat solid tumors."

Final copies of the two posters from AACR (Free AACR Whitepaper) can be found on the Pipeline Publications section of the company’s website.

AACR Poster Presentations

Abstract CT054

The MORPHEUS-Liver study (NCT04524871) is a Phase 1b/2 open-label randomized umbrella study designed to evaluate immunotherapy-based combinations as first line therapy in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). As of July 11, 2025, six patients had been randomized to the triple combination of muzastotug (6 mg/kg Q6W), atezolizumab and bevacizumab and 40 patients had received atezolizumab and bevacizumab in the active control arm. Interim results from patients in the muzastotug arm (18.8 months median duration of follow-up) demonstrated a 66.7% overall response rate (ORR; 4/6) using HCC-specified modified RECIST v1.1 criteria1. ORR was 50.0% (3/6) using RECIST v1.1 criteria. The median progression free survival (mPFS) was 8.2 months (same for both RECIST criteria) and the median overall survival (mOS) was not yet reached at the data cut but was greater than 22 months.

These results compared favorably to the 40 patients in the active control arm (17.2 months median duration of follow-up) that demonstrated an ORR of 32.5% (13/40) using HCC-specified modified RECIST v1.1 criteria, mPFS of 5.5 months, and mOS of 17.5 months. Using RECIST v1.1 criteria, the ORR was 17.5% (7/40) and the mPFS was 4.3 months. The mOS in the doublet control arm was largely overlapping with that reported in the IMbrave150 Phase 3 study2,3 (19.2 months), which served as the basis for approval of atezolizumab (Tecentriq) for HCC in 20204.

The triplet regimen of muzastotug, atezolizumab and bevacizumab was well-tolerated with safety data comparable to the doublet active control arm of atezolizumab and bevacizumab. Grade 3 or greater TRAEs were 50% (3/6) in the muzastotug arm and 45% (18/40) in the active control arm, which supports the potential for continuous dosing with muzastotug. Muzastotug was safely administered continuously at 6 mg/kg Q6W in a triplet setting, which is twice the dose of ipilimumab in the currently approved HCC doublet regimen, (capped at 3 mg/kg Q3W for only 4 cycles)5. In addition, encouraging durability was observed with responses maintained beyond 84 weeks in some patients. Ongoing muzastotug plus atezolizumab treatment after bevacizumab discontinuation suggests potential flexibility to modify individual agents during safety-related interruptions while preserving durable clinical benefit.

Abstract CT083

A Phase 1b/2 single arm study (NCT05405595) is evaluating the triple combination of muzastotug, pembrolizumab and fruquintinib in patients with advanced and metastatic microsatellite stable (MSS) colorectal cancer (CRC). As of February 21, 2026, nine patients have been treated with the triple combination — four (4) patients at a dose of 10 mg/kg every 6 weeks (Q6W) of muzastotug and five (5) patients at a dose of 15 mg/kg Q6W of muzastotug. All patients were without liver metastases (NLM). Interim results demonstrated a 25% ORR (1/4) among patients in the 10 mg/kg arm (6.7 months median follow-up), and a 40% ORR (2/5) among patients in the 15 mg/kg arm (5.9 months median follow-up).

The triplet regimen was well-tolerated with no new safety signals relative to known CTLA-4, PD-1, and fruquintinib monotherapy and combination safety data. There were no dose-limiting toxicities, 25 – 60% Grade 3 TRAEs, and no Grade 4 or Grade 5 TRAEs. Given that fruquintinib is known to be active in MSS CRC patients with liver metastases, the triple combination may have therapeutic benefit beyond the NLM population being evaluated in this study.

(Press release, Adagene, APR 17, 2026, View Source [SID1234664466])